New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:07 EDTXNCRXencor's asthma candidate shows posive results in preclinical study
Xencor will present preclinical data comparing activity of XmAb7195 to omalizumab in reducing IgE, a protein responsible for triggering disease activity in asthma and other allergic disorders. The study supports future studies in human clinical trials. The results of the study found that after a single 5 mg/kg intravenous dose of XmAb7195 or omalizumab in chimpanzees, XmAb7195 reduced free IgE to at least 10-fold lower levels than omalizumab. Similar to its effects in humans, omalizumab increased total IgE. In contrast, XmAb7195 rapidly depleted total IgE below quantifiable levels within 1 hour.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
15:36 EDTXNCRXencor price target raised to $22 from $18 at Wedbush
Wedbush raised Xencor's price target to $22 following demonstration of clinical activity for '5871 and '7195. Shares are Outperform rated.
09:06 EDTXNCROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Flextronics (FLEX), up 6%... Coach (COH), up 6.3%... Autoliv (ALV), up 4.3%... Dow Chemical (DOW), up 3.5%... Ford (F), up 0.8%. ALSO HIGHER: McDonald's (MCD), up 3% after announcing CEO change...Xencor (XNCR), up 19% after reporting results from two trials... Pluristem Therapeutics (PSTI), up 8% after providing update and outlook on trials and pipeline... Avon Products (AVP), up 2.3% after naming James Scully as CFO... Omeros (OMER), up 6% after 2.996M share spot secondary priced at $20.03. DOWN AFTER EARNINGS: Alibaba (BABA), down 8%... Qualcomm (QCOM), down 6.8%... Alexion (ALXN), down 1.1% after reporting fourth quarter results, fiscal 2015 guidance, and CEO appointment. ALSO LOWER: Yahoo (YHOO), down 7% following Alibaba earnings report... Venaxis (APPY), down 72% after its APPY1 Test was determined by the FDA to not meet the criteria for substantial equivalence.
08:13 EDTXNCRXencor to host conference call
Subscribe for More Information
07:23 EDTXNCRXencor reports top-line XmAb5871 Phase 1b/2a results
Subscribe for More Information
07:22 EDTXNCRXencor reports XmAb7195 top-line interim Phase 1a results
Xencor reported top-line interim results from a Phase 1a study for XmAb7195. The data show rapid reduction of circulating free IgE levels to below the limit of detection in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also reduced in a parallel fashion. A dose limiting toxicity of transient, asymptomatic thrombocytopenia was observed at the 3.0 mg/kg dose. Two subjects with high pre-dose IgE levels were treated with XmAb7195, one each at 0.75 mg/kg and 3.0 mg/kg doses, and both had reduction of free IgE levels to below the limit of detection lasting for at least one week. XmAb7195 is an anti-IgE monoclonal antibody containing Xencor's proprietary XmAb Immune Inhibitor Fc domain that targets FcăRIIb, which results in rapid clearance of free and total IgE and inhibition of the function of IgE expressing B cells.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use